



ASX and Media Release

## **Viralytics to Present CAVATAK® Studies at the 2017 Society for Immunotherapy of Cancer Annual Meeting**

---

**31 October 2017, Sydney, Australia:** Viralytics Limited (ASX: VLA, OTCQX: VRACY) today announced that the company will present new data from CAVATAK® studies at the upcoming [32<sup>nd</sup> Annual Meeting of the Society for Immunotherapy of Cancer \(SITC\)](#), which will take place 8-12 November at National Harbor MD, United States. These presentations represent results from clinical trials and a preclinical study on CAVATAK in combination with various immunotherapies, including the immune checkpoint inhibitors pembrolizumab and an IDO blocker.

"The data to be presented at SITC will build on our trial programme narrative as well as point to new areas of opportunity for CAVATAK." said Managing Director Malcolm McColl, "The pre-clinical work on combination with IDO inhibitors, as along with our planned trials in new indications, indicate new areas of opportunity for Viralytics."

The Meeting will provide an opportunity to continue dialogue with pharma groups and key opinion leaders regarding commercial opportunities for CAVATAK.

Following are details for each presentation (all times are in US Eastern Standard Time). Copies of the presentations will become available on the company website at the time of the Meeting.

### **Friday, 10 November**

Podium Presentation: "Oncolytic Viruses in Combination with Immunotherapy Approaches"

Presenter: Howard L. Kaufman, MD, FACS.

Concurrent Session 107: Oncolytic Viruses and Intratumoral Therapies

Location: Cherry Blossom Boardroom

5:10 – 5:30 p.m.

### **Saturday and Sunday, 11- 12 November**

Poster Presentation: "CAPRA: A Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients."

Location: Poster Hall – Prince George's Exhibition Hall DE

Time: 12:30 – 8:00 p.m.

Poster Presentation: "Pre-clinical activity of a novel immunotherapy combination of CAVATAK (Coxsackievirus A21), anti-PD1 blockade and an IDO inhibitor in melanoma."

Location: Poster Hall – Prince George's Exhibition Hall DE

12:30 – 8:00 p.m.



### **About the SITC**

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Regarded as the premier destination for knowledge exchange, education and networking in the cancer immunotherapy field, the SITC Annual Meeting provides an unrivalled opportunity to present to, and connect with, key opinion leaders.

### **About Viralytics Ltd:**

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK®, is currently being studied in clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Cocksackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit [www.viralytics.com](http://www.viralytics.com).

### **Enquiries:**

Dr Malcolm McColl  
Chief Executive Officer  
02 9988 4000

Mr Robert Vickery  
Chief Financial Officer  
02 9988 4000